Liquidia Corporation
LQDA
Kedudukan dalam Saham
#4844
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Harga Saham
$34.12
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.05B
Perubahan (1 hari)
-0.67%
Perubahan (1 tahun)
39.61%
Negara
US
Perdagangan Liquidia Corporation (LQDA)
Kategori
Healthcare
Pendapatan untuk Liquidia Corporation (LQDA)
Pendapatan pada Jun 2026 TTM: $149.50M
Menurut laporan kewangan terkini Liquidia Corporation, pendapatan semasa syarikat ialah $149.50M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-78.50M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-41.02M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Liquidia Corporation dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $149.50M | -214.65% |
| 2024 | $-130.39M | 66.10% |
| 2023 | $-78.50M | 91.40% |
| 2022 | $-41.02M | 18.61% |
| 2021 | $-34.58M | -42.14% |
| 2020 | $-59.76M | 25.60% |
| 2019 | $-47.58M | -10.45% |
| 2018 | $-53.14M | 82.26% |
| 2017 | $-29.15M | 82.97% |
| 2016 | $-15.93M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $1.35B | 802.91% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 706.07% |
HK
|
